Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA4 | P22748 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174838 | 1.00 | CA2 (0.54) | CA2CA1CA4CA7MAPT | |
| SCHEMBL3941336 | 0.84 | CA1 (0.53) | CA2CA1CA4CA7MAPT | |
| SCHEMBL20893356 | 0.84 | CA1 (0.53) | CA2CA1CA4CA7MAPT | |
| SCHEMBL3941339 | 0.84 | CA1 (0.53) | CA2CA1CA4CA7MAPT | |
| SCHEMBL11765765 | 0.83 | CA1 (0.55) | CA2CA1CA4CA7MAPT | |
| SCHEMBL21071281 | 0.83 | CA1 (0.55) | CA2CA1CA4CA7MAPT | |
| SCHEMBL19643179 | 0.83 | CA1 (0.55) | CA2CA1CA4CA7MAPT | |
| SCHEMBL9068333 | 0.83 | CA1 (0.52) | CA2CA1CA4CA7MAPT | |
| SCHEMBL29204442 | 0.83 | CA1 (0.55) | CA2CA1CA4CA7MAPT | |
| SCHEMBL15047078 | 0.83 | CA1 (0.52) | CA2CA1CA4CA7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-9603846-B2 | Process for the preparation of apixaban | CADILA HEALTHCARE LIMITED (IN) | 2017-03-28 | — | — | US | disclosed |
| US-20160143894-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | CADILA HEALTHCARE LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160113912-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2016-04-28 | — | — | US | disclosed |
| WO-2014203275-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| US-8415386-B2 | Azolopyrrolone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2010047956-A9 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110195934-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| EP-2346873-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010047956-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | CA2 323/4885CA1 240/4885CA4 269/4885 |
| US-20110195934-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MC1R, MCHR1, MCHR2 | CA2 1612/4885CA1 3235/4885CA4 1218/4885 |
| US-20160143894-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | CYP4X1, CYP4B1, NPPA | CA2 741/4885CA1 693/4885CA4 316/4885 |
| US-20160113912-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | VKORC1, VKORC1L1, F12 | CA2 433/4885CA1 1365/4885CA4 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.